Cannabis ligands that activate CB1 and CB2 receptors alter the MAPK/ERK pathway in glioblastoma cells, which inhibits angiogenesis and promotes apoptosis (Blázquez et al., 2003; Widmer et al., 2008). This evidence concerns the gene CNR1 and glioblastoma.